BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™
BrainsWay Ltd. (NASDAQ: BWAY) reported results from a pilot study on its Deep TMS™ technology in patients with depression and early-stage Alzheimer’s disease. The study showed an 83.3% response rate and 50% remission rate in depressive symptoms, with measurable changes in brain activity. The study was published in the Journal of Geriatric Psychiatry and Neurology.
How this was made
The 30-second read
Why it matters
Early data suggests a strong clinical signal, but commercial relevance hinges on future trials and regulatory approval.
Market read
First‑time disclosure of promising pilot results could spark short‑term price movement and longer‑term valuation re‑rating.
What to watch
Reimbursement uncertainty and competition from other TMS manufacturers could dampen upside.
Background
BrainsWay (NASDAQ:BWAY) announced peer‑reviewed pilot data for its Deep TMS platform in patients with comorbid depression and early‑stage Alzheimer’s.
Ticker impact
BrainsWay disclosed pilot study results showing 83.3% response and 50% remission in depression for patients with early‑stage Alzheimer’s after 36 Deep TMS sessions.
Potential short‑term upside of 5‑10% if market prices in the data; longer‑term upside depends on subsequent trial outcomes.
The study is small (12 patients) and not yet FDA‑cleared for Alzheimer’s, so impact is limited but the high response rate is noteworthy for a listed neuro‑stimulation firm.
Market effects
May increase interest in neuro‑stimulation and psychiatric‑device sector, prompting analysts to revisit peers.
US and Israeli markets could see modest buying pressure on related biotech stocks.
Highlights growing focus on non‑invasive brain therapies worldwide.
Counterpoint
The pilot’s tiny sample size and lack of FDA clearance limit material impact; investors should wait for larger, controlled trials.
Key entities
- companyBrainsWay Ltd.
NASDAQ‑listed neuro‑stimulation device maker.
- executiveHadar Levy
Chief Executive Officer of BrainsWay.
